Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
68.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 1.00 (1.471%)
Market Cap: £311.75m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Director Shareholding

10 Apr 2007 11:59

Avacta Group plc ("Avacta" or the "Company") Directors' Share Dealings

The Company was informed on 5th April 2007 that, pursuant to the Company's recent placing which became effective on the same day, the following directors of the Company purchased in aggregate 3,400,000 ordinary shares of 0.1p each in the Company ("Ordinary Shares") at the placing price of 2.5p per Ordinary Share. The individual purchases and the resulting interests of the directors are set out below:

Director No. of Ordinary Shares Total shareholding % of issued purchased share capital Gwyn Humphreys 2,000,000 13,125,836 1.69 Alastair Smith 400,000 49,617,468 6.38 Simon Webster 200,000 48,824,258 6.28 Kurt Baldwin 200,000 48,824,258 6.28 Tim Sykes 200,000 3,118,718 0.40 Anthony Robards 400,000 8,891,102 1.14Enquiries:Avacta Group plc Tel: 0870 835 4367 Alastair Smith, Chief Executive WH Ireland Limited Tel: 0161 832 2174 David Youngman, Director, Corporate Finance BankOra Limited Tel: 020 7099 1943 Henry Turcan, Director Nexus Financial Ltd Tel: 020 7451 7050 Nicholas Nelson, Director Mob: 07921 522 920 nicholas.nelson@nexusgroup.co.uk10 April 2007

AVACTA GROUP PLC
Date   Source Headline
23rd Feb 20237:00 amRNSAvacta Therapeutics Division Science Day
13th Feb 20237:00 amRNSIssue of Equity and Total Voting Rights
23rd Jan 202312:20 pmRNSIssue of Equity and Total Voting Rights
17th Jan 20232:05 pmRNSSecond Price Monitoring Extn
17th Jan 20232:00 pmRNSPrice Monitoring Extension
17th Jan 202311:05 amRNSSecond Price Monitoring Extn
17th Jan 202311:00 amRNSPrice Monitoring Extension
17th Jan 20239:05 amRNSSecond Price Monitoring Extn
17th Jan 20239:00 amRNSPrice Monitoring Extension
17th Jan 20237:00 amRNSSuccessful Completion of Fourth Dose Escalation
16th Jan 202310:15 amRNSBlock Listing Application to AIM
19th Dec 20227:00 amRNSAvacta to Host Therapeutics Division Science Day
8th Nov 20227:01 amRNSDirector/PDMR Shareholding
8th Nov 20227:00 amRNSResult of the Open Offer
31st Oct 20221:32 pmRNSAvacta to Present at Theranostics FAP Summit
31st Oct 202211:05 amRNSSecond Price Monitoring Extn
31st Oct 202211:00 amRNSPrice Monitoring Extension
28th Oct 20227:00 amRNSBlock Listing Six Monthly Return
20th Oct 20228:01 amRNSDirector/PDMR Shareholding
20th Oct 20228:01 amRNSAdmission of the Company’s Ordinary Shares
20th Oct 20227:00 amRNSPosting of the Company’s Open Offer Circular
18th Oct 202211:49 amRNSResult of Placing
18th Oct 20229:16 amRNSPrivate CB and ABB Launch
18th Oct 20229:14 amRNSProposed acquisition of Launch Diagnostics
29th Sep 20227:00 amRNSInterim Results for the Period Ended 30 June 2022
26th Sep 20227:00 amRNSNotice of Results
5th Sep 20227:00 amRNSAVA6000 receives Orphan Drug Designation from FDA
1st Sep 20227:00 amRNSPhase I study of AVA6000 advances to fourth cohort
21st Jul 20227:00 amRNSAffyXell successfully completes funding round
30th Jun 20227:00 amRNSLG Chem renews license triggers payment to Avacta
29th Jun 20229:05 amRNSSecond Price Monitoring Extn
29th Jun 20229:00 amRNSPrice Monitoring Extension
29th Jun 20227:00 amRNSSecond dose escalation in phase 1 trial of AVA6000
23rd Jun 20224:41 pmRNSSecond Price Monitoring Extn
23rd Jun 20224:36 pmRNSPrice Monitoring Extension
23rd Jun 20224:27 pmRNSResult of Annual General Meeting
16th Jun 20224:41 pmRNSSecond Price Monitoring Extn
16th Jun 20224:36 pmRNSPrice Monitoring Extension
31st May 20227:00 amRNSPosting of Annual Report and Notice of AGM
16th May 202212:00 pmRNSAffyXell expands partnership with GenScript ProBio
11th May 20227:00 amRNSLondon Therapeutics headquarters established
6th May 20227:00 amRNSBlock Listing Application to AIM (update)
28th Apr 20221:53 pmRNSBlock Listing Application to AIM
14th Apr 20225:01 pmRNSIssue of Equity and Total Voting Rights
14th Apr 202211:29 amRNSIssue of Equity and Total Voting Rights
13th Apr 20227:00 amRNSAffyXell milestone and increased equity stake
12th Apr 20227:00 amRNSPoster presented at the AACR available to download
11th Apr 20224:41 pmRNSSecond Price Monitoring Extn
11th Apr 20224:35 pmRNSPrice Monitoring Extension
11th Apr 20222:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.